BOTHELL, Wash.--(BUSINESS WIRE)--April 19, 2006--Alder Biopharmaceuticals Inc., an early-stage antibody therapeutics company, today announced the appointment of Clay B. Siegall, Ph.D., to its board of directors. “Dr. Siegall is an industry leader and a pioneer in the research and development of targeted cancer therapies,” said Dr. Randall Schatzman, Alder CEO and co-founder. “He brings deep experience in the field of antibody therapeutics, and his entrepreneurial work with Seattle Genetics has given him extensive, firsthand knowledge of how to build a successful biotechnology company. We’re excited to add his insights and knowledge to our board.”
